14 May 2012, BioSpectrum Bureau , BioSpectrum
Singapore: Dr Ben-Zion Weiner, special adviser to the CEO of Teva Pharmaceutical Industries, has been appointed as a non-executive director by Mesoblast. Dr Weiner has been leading Teva's global R&D for over 30 years, maily as chief R&D officer and a member of the Teva executive committee. In this role, he has directly overseen all pharmaceutical R&D and innovative branded product pipeline development.
Dr Weiner has been responsible for the development of hundreds of generic products for the US, EU and other markets. In parallel, he has been responsible for the development and regulatory approval of Teva's innovative product portfolio. Dr Weiner has twice been the recipient of the Rothschild prize for innovation, including for the commercialization of Copaxone in the treatment of multiple sclerosis.
Dr Weiner said, "I am happy and proud to be a Board member of Mesoblast. I trust that stem cell technology is the future of medicine, and that Mesoblast is at the cutting edge of this exciting new field.
"I believe that Mesoblast's unique technology and professional execution capabilities have the potential to deliver multiple innovative biologic products across a broad range of clinical indications," added Dr Weiner.
Mesoblast chairman, Mr Brian Jamieson, said that, "Dr Weiner's extensive pharmaceutical industry experience and his current role as special adviser to the Teva CEO make him a very valuable and strategic addition to the Board. We also acknowledge the important contributions and insights provided by Teva's retiring board representative, Mr Kevin Buchi, and wish him well.
"As Mesoblast expands its clinical product portfolio and approaches product commercialization, we will continue to broaden the mix of skills and international expertise of our directors to ensure that the board is in the best position to deliver maximal shareholder value."